Next Article in Journal
Coronavirus Genomics and Bioinformatics Analysis
Next Article in Special Issue
Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B
Previous Article in Journal
Antiviral Strategies for Pandemic and Seasonal Influenza
Previous Article in Special Issue
Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel
Open AccessReview

Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets

1
Hepatitis C Laboratory, Center of Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, 1, rue du professeur Calmette, BP447, 59021 Lille, France
2
Institute of Biochemistry of the Romanian Academy, Splaiul Independentei 296, 060031, Bucharest, Romania
*
Author to whom correspondence should be addressed.
Viruses 2010, 2(8), 1782-1803; https://doi.org/10.3390/v2081782
Received: 15 June 2010 / Revised: 16 July 2010 / Accepted: 4 August 2010 / Published: 24 August 2010
(This article belongs to the Special Issue Antivirals Against Hepatitis C Virus)
Chronic Hepatitis C infection is a global health problem. While primary infection is often inapparent, it becomes chronic in most cases. Chronic infection with Hepatitis C virus (HCV) frequently leads to liver cirrhosis or liver cancer. Consequently, HCV infection is one of the leading causes for liver transplantation in industrialized countries. Current treatment is not HCV specific and is only effective in about half of the infected patients. This situation underlines the need for new antivirals against HCV. To develop new and more efficient drugs, it is essential to specifically target the different steps of the viral life cycle. Of those steps, the targeting of HCV assembly has the potential to abolish virus production. This review summarizes the advances in our understanding of HCV particle assembly and the identification of new antiviral targets of potential interest in this late step of the HCV life cycle. View Full-Text
Keywords: Hepatitis C; assembly; release; antivirals Hepatitis C; assembly; release; antivirals
Show Figures

Figure 1

MDPI and ACS Style

Tews, B.A.; Popescu, C.-I.; Dubuisson, J. Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets. Viruses 2010, 2, 1782-1803. https://doi.org/10.3390/v2081782

AMA Style

Tews BA, Popescu C-I, Dubuisson J. Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets. Viruses. 2010; 2(8):1782-1803. https://doi.org/10.3390/v2081782

Chicago/Turabian Style

Tews, Birke Andrea; Popescu, Costin-Ioan; Dubuisson, Jean. 2010. "Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets" Viruses 2, no. 8: 1782-1803. https://doi.org/10.3390/v2081782

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop